Mario Balsa

Mario Balsa: A PI3K Path Worth Walking – If You Can Manage the Steps

Mario Balsa, Medical Oncology Resident at Catalan Institute of Oncology (ICO), shared a post on X:

“INAVO120 (NEJM): In PIK3CA-mutated, HR+/HER2– endocrine-resistant MBC, inavolisib + palbociclib + fulvestrant vs placebo:

  • mOS: 34.0 vs 27.0 mo (HR 0.67; p=0.02)
  • Higher AEs: 6.8% d/c due to toxicity

A PI3K path worth walking – if you can manage the steps.

Congrats to Komal Jhaveri and all the team!”

Title: Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer

Journal: NEJM

Authors: Komal L. Jhaveri, Seock-Ah Im, Cristina Saura, Sibylle Loibl, Kevin Kalinsky, Peter Schmid, Sherene Loi, Eirini Thanopoulou, Noopur Shankar, Yanling Jin, Thomas J. Stout, Tiffany D. Clark, Chunyan Song, Dejan Juric, Nicholas C. Turner

Read the full article.

Mario Balsa

More posts featuring Mario Balsa on OncoDaily.

cancer Catalan Institute of Oncology Chunyan Song Cristina Saura Dejan Juric Eirini Thanopoulou Fulvestrant ICO INAVO120 Inavolisib Kevin Kalinsky Komal Jhaveri Komal L. Jhaveri Mario Balsa Nicholas C. Turner Noopur Shankar OncoDaily Oncology palbociclib Peter Schmid PIK3CA-mutated breast cancer Seock-Ah Im Sherene Loi Sibylle Loibl Thomas J Stout Tiffany D. Clark Yanling Jin